BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

A panel of experts reviews how the recent approval of teclistamab, a bispecific antibody, has changed the treatment landscape for patients with multiple myeloma.

Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

Rahul Banerjee, MD, FACP, discusses a recent presentation from the Tandem meeting regarding BCMA CAR T-cell therapy in patients with multiple myeloma.

CancerNetwork®’s podcast dives into an article focused on treatment options for older, transplant-ineligible patients with multiple myeloma.

The investigational CAR T-cell therapy equecabtagene autoleucel receives fast track and regenerative medicine advanced therapy designations for managing relapsed or refractory multiple myeloma.

Survival appears to be significantly improved when idecabtagene vicleucel is given vs standard of care in relapsed/refractory multiple myeloma.